Have a feature idea you'd love to see implemented?
Let us know!
AKBA Akebia Therapeutics Inc
Price (delayed)
$1.83
Market cap
$399.27M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.23
Enterprise value
$408.54M
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is
Highlights
The company's quick ratio has surged by 55% QoQ and by 16% YoY
AKBA's debt is down by 18% year-on-year and by 2.3% since the previous quarter
Akebia Therapeutics's EPS has increased by 30% YoY but it has decreased by 10% from the previous quarter
AKBA's net income is up by 22% YoY but it is down by 14% from the previous quarter
The equity is down by 49% since the previous quarter and by 28% year-on-year
AKBA's gross profit is down by 24% year-on-year
Key stats
What are the main financial stats of AKBA
Market
Valuations
Earnings
Shares outstanding
218.18M
Market cap
$399.27M
Enterprise value
$408.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.27
EV/EBIT
N/A
EV/EBITDA
31.79
EV/Sales
2.4
Revenue
$169.88M
Gross profit
$108.4M
Net income
-$45.99M
EBIT
-$33.27M
EBITDA
$12.85M
Free cash flow
-$38.53M
Per share
Balance sheet
Liquidity
EPS
-$0.23
EPS diluted
-$0.23
Free cash flow per share
-$0.18
Book value per share
-$0.24
Revenue per share
$0.81
TBVPS
$0.66
Total assets
$207.14M
Total liabilities
$257.54M
Debt
$43.29M
Equity
-$50.4M
Working capital
$34.41M
Debt to equity
-0.86
Current ratio
1.52
Quick ratio
1.01
Net debt/EBITDA
0.72
Margins
Efficiency
Dividend
EBITDA margin
7.6%
Gross margin
63.8%
Net margin
-27.1%
Operating margin
-17.3%
Return on assets
-20.6%
Return on equity
N/A
Return on invested capital
-55.6%
Return on capital employed
-23.5%
Return on sales
-19.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AKBA stock price
How has the Akebia Therapeutics stock price performed over time
Intraday
2.23%
1 week
-1.08%
1 month
2.23%
1 year
52.5%
YTD
47.58%
QTD
38.64%
Financial performance
How have Akebia Therapeutics's revenue and profit performed over time
Revenue
$169.88M
Gross profit
$108.4M
Operating income
-$29.31M
Net income
-$45.99M
Gross margin
63.8%
Net margin
-27.1%
The operating income is up by 38% year-on-year
The operating margin has grown by 29% YoY
AKBA's gross profit is down by 24% year-on-year
AKBA's net income is up by 22% YoY but it is down by 14% from the previous quarter
Growth
What is Akebia Therapeutics's growth rate over time
Valuation
What is Akebia Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.27
EV/EBIT
N/A
EV/EBITDA
31.79
EV/Sales
2.4
Akebia Therapeutics's EPS has increased by 30% YoY but it has decreased by 10% from the previous quarter
The equity is down by 49% since the previous quarter and by 28% year-on-year
The price to sales (P/S) is 51% more than the last 4 quarters average of 1.5 and 42% more than the 5-year quarterly average of 1.6
Akebia Therapeutics's revenue has decreased by 13% YoY and by 2.6% QoQ
Efficiency
How efficient is Akebia Therapeutics business performance
Akebia Therapeutics's ROS has increased by 27% YoY but it has decreased by 3.7% from the previous quarter
The return on invested capital is up by 20% year-on-year and by 10% since the previous quarter
The ROA has contracted by 18% from the previous quarter
Dividends
What is AKBA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AKBA.
Financial health
How did Akebia Therapeutics financials performed over time
AKBA's total assets is 20% smaller than its total liabilities
The company's quick ratio has surged by 55% QoQ and by 16% YoY
Akebia Therapeutics's current ratio has increased by 46% QoQ and by 10% YoY
AKBA's debt is 186% greater than its equity
The equity is down by 49% since the previous quarter and by 28% year-on-year
The debt to equity has increased by 36% year-on-year and by 34% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.